From the INTERNATIONAL SEARCHING AUTHORITY

To: JOHN S. PRATT KILPATRICK STOCKTON, LLC SUITE 2800 1100 PEACHTREE STREET ATLANTA, GA 30309	PCT NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION (PCT Rule 44.1) Date of mailing			
Applicant's or agent's file reference 51687-0261WP	(day/month/year) FOR FURTHER ACTION See paragraphs 1 and 4 below			
International application No. PCT/US04/43092	International filing date (day/month/year) 24 December 2004 (24.12.2004)			
Applicant TRANSGENRX, INC.	(44)			
 The applicant is hereby notified that the international sea have been established and are transmitted herewith. 	rch report and the written opinion of the International Searching Authority			
Filing of amendments and statement under Article 19 The applicant is entitled, if he so wishes, to amend the cli	: nims of the international application (see Rule 46):			
When? The time limit for filing such amendments is search report.	normally two months from the date of transmittal of the international			
Where? Directly to the International Bureau of WIPe 1211 Geneva 20, Switzerland, Facsimile No				
For more detailed instructions, see the notes on the				
2. The applicant is hereby notified that no international sear Article 17(2)(a) to that effect and the written opinion of	rch report will be established and that the declaration under the International Searching Authority are transmitted herewith.			
3. With regard to the protest against payment of (an) add	itional fee(s) under Rule 40.2, the applicant is notified that:			
the protest together with the decision thereon has be request to forward the texts of both the protest and	een transmitted to the International Bureau together with the applicant's the decision thereon to the designated Offices.			
no decision has been made yet on the protest; the ap	oplicant will be notified as soon as a decision is made.			
4. Reminders Shortly after the expiration of 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.				
The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.				
Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.				
In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.				
See the Annex to Form PCT/IB/301 and, for details about the a Volume II, National Chapters and the WIPO Internet site.	applicable time limits, Office by Office, see the PCT Applicant's Guide,			
Name and mailing address of the ISA/ US	Authorized officer Fereydoun G. Sajjadi			
Mail Stop PCT, Attn: ISA/US Commissioner for Patents	Fereydoun G. Sajjadi			
P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201	Telephone No. (571) 272-1600			

Form PCT/ISA/220 (January 2004)

(See notes on accompanying sheet)

Docketed for: 1-1-06
Entered on: 5/2-8/06
Initials: Previously Entered:

RCVD MAY 15 '06

From the INTERNATIONAL SEARCHING AUTHORITY

To: JOHN S. PRATT	PCT			
KILPATRICK STOCKTON, LLC SUITE 2800 1100 PEACHTREE STREET ATLANTA, GA 30309	NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION			
	(PCT Rule 44.1)			
	Date of mailing (day/month/year) 11 MAY 2006			
Applicant's or agent's file reference 51687-0261WP	FOR FURTHER ACTION See paragraphs 1 and 4 below			
International application No. PCT/US04/43092	International filing date (day/month/year) 24 December 2004 (24.12.2004)			
Applicant TRANSGENRX, INC.				
The applicant is hereby notified that the international sca have been established and are transmitted herewith.	rch report and the written opinion of the International Searching Authority			
Filing of amendments and statement under Article 19 The applicant is entitled, if he so wishes, to amend the cl	e: aims of the international application (see Rule 46):			
When? The time limit for filing such amendments i search report.	s normally two months from the date of transmittal of the international			
Where? Directly to the International Bureau of WIP 1211 Geneva 20, Switzerland, Facsimile No.				
For more detailed instructions, see the notes on the	accompanying sheet.			
2. The applicant is hereby notified that no international sea Article 17(2)(a) to that effect and the written opinion of	rch report will be established and that the declaration under the International Searching Authority are transmitted herewith.			
3. With regard to the protest against payment of (an) add	litional fee(s) under Rule 40.2, the applicant is notified that:			
the protest together with the decision thereon has be request to forward the texts of both the protest and	een transmitted to the International Bureau together with the applicant's the decision thereon to the designated Offices.			
no decision has been made yet on the protest; the a	pplicant will be notified as soon as a decision is made.			
4. Reminders				
Shortly after the expiration of 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.				
The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.				
Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.				
In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.				
See the Annex to Form PCT/IB/301 and, for details about the Volume II, National Chapters and the WIPO Internet site.	applicable time limits, Office by Office, see the PCT Applicant's Guide,			
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450	Authorized officer Fereydoun G. Sajjadi			
Alexandria, Virginia 22313-1450	Telephone No. (571) 272-1600			

Facsimile No. (571) 273-3201 Form PCT/ISA/220 (January 2004)

(See notes on accompanying sheet)

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference FOR FURTHER see Form PCT/ISA/220 1687-0261WP ACTION as well as, where applicable, item 5 below.			
nternational application No. International filing date (day/month/year) (Earliest) Priority Date (day/month/y 24 December 2004 (24.12.2004) 24 December 2003 (24.12.2003)			
Applicant TRANSGENRX, INC.			
This international search report consists of It is also accompanied 1. Basis of the Report a. With regard to the language, the international a a translation of the of a translation fit b. With regard to any nucleotic Certain claims were found 2. Certain claims were found 3. Unity of invention is lacking the text is approved as submether than the text has been established	by a copy of each prior art document cited international search was carried out on the bas application in the language in which it was file international application into	in this report. is of: ed. , which is the language ch (Rules 12.3(a) and 23.1(b))	
5. With regard to the abstract, the text is approved as subm		and the same in Box No IV. The analysis	
may, within one month from	l, according to Rule 38.2(b), by this Authority the date of mailing of this international searc	as it appears in Box No. IV. The applicant h report, submit comments to this Authority.	
as suggested by the	Authority, because the applicant failed to sugg Authority, because this figure better characteri	gest a figure.	

Form PCT/ISA/210 (first sheet) (April 2005)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/43092

Box No		Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This inte	mation	al search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.		Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2.	t	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.		Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No	. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
See PCT		nal Searching Authority found multiple inventions in this international application, as follows:
1. [_ 2. [_ 3. [∑		As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of any additional fees. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 1-7,12-20,22 and 23
4. Remar 8		No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee. The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
5		V V V V V V V V V V V V V V V V V V V
		No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(2)) (April 2005)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/43092

A. CLASSIFICATION OF SUBJECT MATTER 1PC: A01K 67/00(2006.01),67/027(2006.01)				
USPC: 800/008,19 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) U.S.: 800/008,19				
Documentation searched other than minimum documentation to the e	extent that such documents are included in	the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN, MEDLINE, BIOSCIENCE, MEDICINE, EMBASE, BIOSIS, SCISEARCH				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category * Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.		
X US 5,719,055 (COOPER) 17 February 1998 (17.2.19)	98), entire document.	1-4, 6-7, 12-13, 15-19, 22-23		
X HOUDEBINE, L. The Methods to Generate Animals Biotech. 2002 Vol 98. pages 146-147.	5, 14			
A RICHARDSON, P.D. Gene Repair and Transposon-N pages 112-115.	dediated Gene Therapy, 2002, Voi 20.	20		
Further documents are listed in the continuation of Box C.	See patent family annex.			
Special categories of cited documents. "A" document defining the general state of the art which is not considered to be of	later document published after the inte date and not in conflict with the applic principle or theory underlying the inve	ation but cited to understand the		
particular relevance "E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be conside when the document is taken alone			
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means	"Y" document of particular relevance; the considered to involve an inventive ste combined with one or more other such being obvious to a person skilled in the	p when the document is a documents, such combination		
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent			
Date of the actual completion of the international search	Date of mailing of the international sear			
07 April 2006 (07.04.2006)		06 9/		
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US	Authorized officer	Il Houng		
Commissioner for Patents P.O. Box 1450	Fereydoun G. Sajjadi Telephone No. (571) 272-1600			
Alexandría, Virginia 22313-1450 Facsimile No. (571) 273-3201				

rom the NTERNATIONAL SEARCHING AUT	HORITY			
To: JOHN S. PRATT KILPATRICK STOCKTON, LLC SUITE 2800		PCT WRITTEN OPINION OF THE		
1100 PEACHTREE STREET ATLANTA, GA 30309		}	ONAL SEARCHING AUTHORITY	
			(PCT Rule 43bis.1)	
		Date of mailing (day/month/year)	11 MAY 2006	
Applicant's or agent's file reference		FOR FURTHER ACTION		
51687-0261WP			See paragraph 2 below	
International application No.	International filing date	(day/month/year)	Priority date (day/month/year)	
PCT/US04/43092	24 December 2004 (24.		24 December 2003 (24.12.2003)	
International Patent Classification (IPC	•	tion and IPC		
IPC: A01K 67/00(2006.01),67/02 USPC: 800/8.19	7(2006.01)			
Applicant				
TRANSGENRX, INC.				
This opinion contains indications r	elating to the following iter	ms:		
Box No. 1 Basis of t	he opinion			
Box No. II Priority				
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
Box No. IV Lack of u	Box No. IV Lack of unity of invention			
Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
Box No. VI Certain d	ocuments cited			
Box No. VII Certain d	efects in the international a	pplication		
Box No. VIII Certain o	bservations on the internation	onal application		
2. FURTHER ACTION				
International Preliminary Exami	ning Authority ("IPEA") to the IPEA and the choser	except that this does IPEA has notified the	be considered to be a written opinion of the not apply where the applicant chooses an le International Bureau under Rule 66.1bis(b) ered.	
	ere appropriate, with amen	dments, before the ex	PEA, the applicant is invited to submit to the epiration of 3 months from the date of mailing whichever expires later.	
For further options, see Form PC7	7/ISA/220.			
3. For further details, see notes to Fo	rm PCT/ISA/220.			
Name and mailing address of the ISA	US Date of comp	letion of this opinion	Authorized officer	
Mail Stop PCT, Attn: ISA/US		5 (13.04.2006)	Authorized officer Fereydoun G. Sajjadi	
Commissioner for Patents P.O. Box 1450		(13.04.2000)		
Alexandria, Virginia 22313-145 Facsimile No. (571) 273-3201	1		Telephone No. (571) 272-1600	
Form PCT/ISA/237 (cover sheet) (April	2005)		<u> </u>	

International application No.

PCT/US04/43092

Box No	o. I Basis of this opinion
1. With r	regard to the language, this opinion has been established on the basis of:
\boxtimes	the international application in the language in which it was filed
	a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed tion, this opinion has been established on the basis of:
a.	type of material
	a sequence listing
	table(s) related to the sequence listing
Ь.	format of material
	on paper
	in electronic form
¢.	time of filing/furnishing
	contained in the international application as filed.
	filed together with the international application in electronic form.
	furnished subsequently to this Authority for the purposes of search.
3.	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Addit	ional comments:

International application No.

PCT/US04/43092

Bo	ox No. IV Lack of unity of invention
1.	In response to the invitation (Form PCT/ISA/206) to pay additional fees the applicant has, within the applicable time lim paid additional fees paid additional fees under protest and, where applicable, the protest fee
	paid additional fees under protest but the applicable protest fee was not paid
	not paid additional fees
2.	This Authority found that the requirement of unity of invention is not complied with and chose not to invite the applican pay additional fees.
3.	This Authority considers that the requirement of unity of invention in accordance with Rule 13.1, 13.2 and 13.3 is
	complied with
	not complied with for the following reasons: See the lack of unity section of the International Search Report (Form PCT/ISA/210)
	See the lack of unity section of the International Search Report(Form PCT/ISA/210)
4. (Consequently, this opinion has been established in respect of the following parts of the international application:
	all parts.
	the parts relating to claims Nos. 1-7,12-20,22 and 23

International application No. PCT/US04/43092

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
1. Statement				
Novelty (N)		5, 14, 20 1-4, 6-7, 12-13, 15-19, 22-23		
Inventive step (IS)	Claims Claims	20 1-7, 12-19, 22-23		
Industrial applicability (IA)	Claims Claims	1-7, 12-20, 22-23 NONE	NO	
2. Citations and explanations: Please See Continuation Sheet				
		•		

International application No. PCT/US04/43092

Supplemental Box	
In case the space in any of the preceding boxes is not sufficient.	

V. 2. Citations and Explanations:

Claims 1-4, 6-7, 12-13, 15-19, and 22-23, lack novelty under PCT Article 33(2) as being anticipated by Cooper Cooper teaches the claimed composition as a vector for inserting an exogenous gene into a chromosome of a eukaryotic cell, comprising: a) a gene encoding a bacterial transposase; b) two transposon insertion sequences recognized by the transposase c) said exogenous gene, wherein said exogenous gene is between the two transposon insertion sequences; and (d) a promoter that is operably linked to said transposase gene; wherein one of said insertion sequences is located between said transposase gene and said exogenous gene; and wherein the transposase expressed by said transposase gene will excise from said vector a fragment comprising the two transposon insertion sequences and the exogenous gene between the two transposon insertion sequences, and will insert the excised fragment into a chromosome of a eukaryotic cell (claim 1, columns 27-28). Cooper describes the transposase as derived from Tn/10 (column 2, line 43; and column 8, line 58), hence it is a bacterial transposase, that is under the control of a modified promoter (column 8, line 43). The transposon-based vector is described by Cooper as capable of enhanced integration of a lytic peptide into a eukaryotic genome (mammalian and fish cells; paragraph 8, lines 23-30). Additionally taught is a constitutive promoter, the 35S cauliflower mosaic virus 5' region-nopaline synthetase-3' polyadenylation cassette control gene expression, for plant transformation (column 7, lines 41-44). Additionally inducible promoters are contemplated by the invention (column 17, lines 28-31). Further described is a construct carrying the gene for the native cecropin peptide and the native cecropin promoter, a construct that can be inducibly expressed in mammalian cells (column 10, lines 55-58). The construction of the plasmid pCEP and transformation of E. coli cells with said plasmid are described in columns 17-20. Cooper further describes the use of their vector for the introduction of eecropin B or Shiva 1 into the mammalian or other vertebrate cells, that enable the transformed cells to produce a chemotherapeutic agent that has a systemic effect on certain pathogens (column 9, lines 51-58). Thus the method of Cooper encompasses gene therapy. In one experiment Cooper states that of 18 potentially transgenic catfish assayed for the presence of cecropin B gene, 9 (or 50%) yielded positive bands for the gene, while none of the 10 negative control fish assayed to date had such a band (column 24, lines 33-37).

Claim 5 lacks an inventive step under PCT Article 33(3) as being obvious over Cooper in view of Houdebine. The composition comprising the transposon vector of Cooper et al. has been addressed. Cooper does not teach the one or more genes of interest in a transposon vector, encode for a nucleic acid which inhibits transcription. Houdebine et al. teach the use of transposons to enhance the integration of foreign DNA in the genome (last paragraph, second column, p. 146). Houdebine et al. further describe the inhibition of endogenous expression by antisense RNAs, wherein RNAi, that is normally a defense mechanism against transposons, may be used in vectors expressing short double stand RNA. Thus, it would have been obvious to one of ordinary skill in this art to apply the RNAi

Form PCT/ISA/237 (Supplemental Box) (April 2005)

International application No. PCT/US04/43092

Supplemental Box


In case the space in any of the preceding boxes is not sufficient.

application of Houdebine to the transposon vector of Cooper et al. to provide a transposon-based vector, wherein the one or more genes of interest encode for a nucleic acid which inhibits transcription.

Claim 14 lacks an inventive step under PCT Article 33(3) as being obvious over Cooper in view of Houdebine. The application of the transposon vector of Cooper et al. for gene therapy has been addressed. Cooper does not teach cell a specific promoter controlling the one or more transgenes of the transposon vector. Houdebine teaches that transposons are potent and flexible tools which might be used for gene therapy (last paragraph, first column, p. 147). Houdebine et al. further address the use of vectors for the conditional expression of transgenes that define where and when a transgene is expressed in animals, and specifically describe several systems using a tissue specific promoter (column 1, p. 153). Thus it would have been obvious to one of ordinary skill in this art to apply the cell specific promoter of Houdebine to the transposon vector and gene therapy of Cooper et al. to provide a method of gene therapy to an animal comprising administering to said animal the said transposon-based vector.

Claim 20 meets the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the claimed means wherein said vector harboring a bacterial transposase is used in a method of gene therapy, wherein the administration occurs through the vascular system.

Claims 1-7, 12-20, and 22-23, meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed may be used for providing gene therapy to an animal to treat a disease or condition.



NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under Article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article," "Rule" and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report and the written opinion of the International Searching Authority, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another except where, e.g. the approximate waters the tatter to be profession for the purposes of provisional protection of has around reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only (see PCT Applicant's Guide, Volume I/A, Annexes B) and B2).

The attention of the applicant is drawn to the fact that amendments to the claims under Article 19 are not allowed where the International Searching Authority has declared, under Article 17(2), that no international search report would be established (see PCT Applicant's Guide, Volume I/A, paragraph 296)

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Preliminary Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having When? been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one How? or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Section 205(b))

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)")

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new.
- (iv) the claim replaces one or more claims as filed,
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]: "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged, new claims 49 to 51 added.
- [Where originally there were 15 claims and after amendment of all claims there are 11] Claims 1 to 15 replaced by amended claims 1 to 11
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]: "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims !! to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added.

"Statement under Article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

If a demand for international preliminary examination is made, the written opinion of the International Searching Authority will, except in certain cases where the International Preliminary Examining Authority did not act as International Searching Authority and where it has notified the International Bureau under Rule 66 I bis(b), be considered to be a written opinion of the International Preliminary Examining Authority. If a demand is made, the applicant may submit to the International Preliminary Examining Authority a reply to the written opinion together, where appropriate, with amendments before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later (Rule 43 bis. 1(c)).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see the PCT Applicant's Guide, Volume II.